Lytix Biopharma’s abstract with preliminary interim Phase II data from the ATLAS-IT-05 study is published.

Oslo, 16 October 2023. Lytix Biopharma – Lytix Biopharma AS (“Lytix”) (Euronext Growth Oslo: LYTIX), a clinical stage immuno-oncology company, announces that an abstract for a poster presentation at the ESMO Congress 2023 today has been published online on the ESMO website.After the submission of the abstract, the data set to be included in the poster presentation on Monday 23 October was expanded. The majority of the patients are still early in the treatment course, and responses will continue to evolve. Details for the poster session are as follows: Abstract Title: Intratumoral